Vimarsana
Biggest News Aggregation in the World

Page 2 - Ongoing Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ongoing Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ongoing Review Today - Breaking & Trending Today

Embattled Rite Aid Faces Delisting From NYSE - Vimarsana News

Embattled Rite Aid Faces Delisting From NYSE

Rite Aid disclosed it was no longer in compliance with New York Stock Exchange "continued listing standards” and needs to take measures to boost its share price to regain good standing.

Source: forbes.com
Rite Aid Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Standards - Vimarsana News

Rite Aid Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Standards

Rite Aid Corporation announced today that the New York Stock Exchange informed the Company that it is no longer in compliance with NYSE continued listing standards set forth in Section 802.01B ,...

Polished.com Announces Filing of Restated and Delayed Financial Statements and Release of Results for Q1 2023 - Vimarsana News

Polished.com Announces Filing of Restated and Delayed Financial Statements and Release of Results for Q1 2023

Filings Position Company to Meet Reporting Obligations and Retain Listing on NYSE American Provides Estimated Financials for Q2 2023 and Updated Outlook for the Full Year Secures Amendment to May...

Viaplay Group announces new operating model - Vimarsana News

Viaplay Group announces new operating model

Having begun the month shocking the video industry with the resignation of CEO Anders Jensen and a downgrade of its short-term outlook, Viaplay Group has ended ...

FDA Issues Complete Response Letter for Aflibercept 8 mg as AMD, DME Treatment - Vimarsana News

FDA Issues Complete Response Letter for Aflibercept 8 mg as AMD, DME Treatment

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.